June 22 (Reuters) - Kalytera Therapeutics Inc KALY.V :
* Kalytera Therapeutics Inc - Robert Farrell, J.D., president and cfo of Kalytera, will assume role of interim chief executive officer
* Kalytera Therapeutics - anticipates it will begin patient enrollment in a phase 2 clinical study evaluating cbd for prevention of gvhd in h2 of 2017
* Kalytera Therapeutics - Andrew L. Salzman, m.d., who previously served as CEO will be leaving company, effective june 21, 2017 Source text for Eikon: ID:nGNXNXKCJa Further company coverage: KALY.V